RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
JAMA ONCOLOGY
Collezione AO Ordine Mauriziano

Items : 5

Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. in JAMA oncology / JAMA Oncol. 2023 Jul 1;9(7):966-970. doi: 10.1001/jamaoncol.2023.0655.

2023
AO Ordine Mauriziano

Ciardiello F; Troiani T; Di Maio M; De Vita F; Altucci L; Marrone F; Santini D; Scartozzi M; Zampino MG; Bordonaro R; Montesarchio V; De Stefano A; Cardone C; Avallone A; Di Liello A; Famiglietti V; Esposito L; Della Corte CM; Ciardiello D; Martinelli E; Martini G; De Falco V; Napolitano S;

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. in JAMA oncology / JAMA Oncol. 2023 Dec 1;9(12):1651-1659. doi: 10.1001/jamaoncol.2023.4003.

2023
AO Ordine Mauriziano

Zhu AX; Vogel A; Abdrashitov R; Finn RS; Boisserie F; Li S; Chen Y; Assenat E; Satoh T; Marino D; Meng Z; Bai Y; Guo Y; Meyer T; Kudo M; Qin S;

The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings. in JAMA oncology / JAMA Oncol. 2020 Jun 1;6(6):926-927. doi: 10.1001/jamaoncol.2020.0475.

2020
AO Ordine Mauriziano

Zichi C; Gargiulo P; Cardone C; De Luca E; Audisio M; Di Maio M; Perrone F;

A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice. in JAMA oncology / JAMA Oncol. 2017 Jun 1;3(6):735-736. doi: 10.1001/jamaoncol.2016.4896.

2017
AO Ordine Mauriziano

Perrone F; Di Maio M; Del Mastro L;

Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology: Beyond Citation Counts in JAMA oncology

2016
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Baratelli C; Tampellini M;